Bioventus Share Price (NASDAQ: BVS)

$7.4

▲

0.15

(2.07%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Bioventus Stock chart to analyse performance

Bioventus stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$7.30
Today's High:$7.45
$7.40
1.35%
Downside
Day's Volatility :2.01%
Upside
0.67%
52 Weeks Low:$5.81
52 Weeks High:$14.38
$7.40
21.49%
Downside
52 Weeks Volatility :59.6%
Upside
48.54%

Bioventus Stock Returns

Period	Bioventus Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	14.83%	3.6%	0.0%
6 Months	-27.14%	-7.7%	0.0%
1 Year	-25.98%	-12.6%	0.0%
3 Years	-0.07%	10.2%	-4.1%

Bioventus Inc Key Stats

Check Bioventus key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$7.25
Open	$7.45
Today's High	$7.45
Today's Low	$7.3
Market Capitalization	$485.0M
Today's Volume	$295.5K
52 Week High	$14.38
52 Week Low	$5.81
Revenue TTM	$564.1M
EBITDA	$61.8M
Earnings Per Share (EPS)	$0.03
PE Ratio	241.67
Profit Margin	0.33%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	1.39%

Stock Returns calculator for Bioventus Stock including INR - Dollar returns

The Bioventus stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Bioventus investment value today

Current value as on today

₹79,358

Returns

₹20,642

(-20.64%)

Returns from Bioventus Stock

₹25,926 (-25.93%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Bioventus Stock

250%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Bioventus Stock from India on INDmoney has increased by 250% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Bioventus Inc

Name
Holdings %
Name
Holdings %
Essex Woodlands Health Ventures
19.47%
Juniper Investment Co, LLC
10.37%
Nantahala Capital Management, LLC
7.89%
BlackRock Inc
4.23%
Vanguard Group Inc
4.19%
Divisadero Street Capital Management, LP
2.53%

Analyst Recommendation on Bioventus Stock

Rating

Trend

Buy

71%Buy

14%Hold

14%Sell

Based on 7 Wall street analysts offering stock ratings for Bioventus(by analysts ranked 0 to 5 stars)

Bioventus Share Price Target

What analysts predicted

Upside of 72.3%

Target:

$12.75

Current:

$7.40

Bioventus share price target is $12.75, a slight Upside of 72.3% compared to current price of $7.40 as per analysts' prediction.

Bioventus Stock Insights

Price Movement
In the last 1 month, BVS stock has moved up by 13.4%
Increasing Revenue
Revenue is up for the last 2 quarters, 123.87M → 147.66M (in $), with an average increase of 16.1% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -2.63M → 7.45M (in $), with an average increase of 135.4% per quarter
BVS vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 29.0% return, outperforming this stock by 55.4%
BVS vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 161.7% return, outperforming this stock by 160.5%
Price to Sales
ForBVS every $1 of sales, investors are willing to pay $0.9, whereas for Boston Scientific Corp., the investors are paying $8.4 for every $1 of sales.

Bioventus Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$340.1M	↑ 6.57%
Net Income	$6.9M	↓ 156.12%
Net Profit Margin	2.01%	↑ 5.83%

	FY20	Y/Y Change
Revenue	$321.2M	↓ 5.58%
Net Income	$16.4M	↑ 139.54%
Net Profit Margin	5.11%	↑ 3.1%

	FY21	Y/Y Change
Revenue	$430.9M	↑ 34.17%
Net Income	$19.4M	↑ 18.06%
Net Profit Margin	4.5%	↓ 0.61%

	FY22	Y/Y Change
Revenue	$512.1M	↑ 18.85%
Net Income	$-158.7M	↓ 919.12%
Net Profit Margin	-30.99%	↓ 35.49%

	FY23	Y/Y Change
Revenue	$512.3M	↑ 0.04%
Net Income	$-156.2M	↓ 1.56%
Net Profit Margin	-30.49%	↑ 0.5%

	FY24	Y/Y Change
Revenue	$573.3M	↑ 11.89%
Net Income	$-33.5M	↓ 78.53%
Net Profit Margin	-5.85%	↑ 24.64%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$129.5M	↓ 4.41%
Net Income	$-4.6M	↓ 25.03%
Net Profit Margin	-3.53%	↑ 0.97%

	Q2 FY24	Q/Q Change
Revenue	$151.2M	↑ 16.81%
Net Income	$-24.0M	↑ 424.99%
Net Profit Margin	-15.87%	↓ 12.34%

	Q3 FY24	Q/Q Change
Revenue	$139.0M	↓ 8.1%
Net Income	$-4.8M	↓ 79.89%
Net Profit Margin	-3.47%	↑ 12.4%

	Q4 FY24	Q/Q Change
Revenue	$153.6M	↑ 10.56%
Net Income	$-156.0K	↓ 96.77%
Net Profit Margin	-0.1%	↑ 3.37%

	Q1 FY25	Q/Q Change
Revenue	$123.9M	↓ 19.37%
Net Income	$-2.6M	↑ 1590.38%
Net Profit Margin	-2.13%	↓ 2.03%

	Q2 FY25	Q/Q Change
Revenue	$147.7M	↑ 19.2%
Net Income	$7.5M	↓ 382.86%
Net Profit Margin	5.05%	↑ 7.18%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$249.2M	↑ 6.04%

	FY20	Y/Y Change
Profit	$233.5M	↓ 6.29%

	FY21	Y/Y Change
Profit	$302.7M	↑ 29.63%

	FY22	Y/Y Change
Profit	$331.1M	↑ 9.37%

	FY23	Y/Y Change
Profit	$328.2M	↓ 0.87%

	FY24	Y/Y Change
Profit	$388.2M	↑ 18.29%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$88.4M	↑ 2.41%

	Q2 FY24	Q/Q Change
Profit	$103.6M	↑ 17.27%

	Q3 FY24	Q/Q Change
Profit	$93.6M	↓ 9.73%

	Q4 FY24	Q/Q Change
Profit	$102.7M	↑ 9.73%

	Q1 FY25	Q/Q Change
Profit	$83.1M	↓ 19.09%

	Q2 FY25	Q/Q Change
Profit	$102.1M	↑ 22.92%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$40.7M	↓ 9.9%
Investing Cash Flow	$-7.9M	↑ 29.68%
Financing Cash Flow	$-11.0M	↓ 17.39%

	FY20	Y/Y Change
Operating Cash Flow	$71.8M	↑ 76.35%
Investing Cash Flow	$-20.5M	↑ 159.1%
Financing Cash Flow	$-29.6M	↑ 170.01%

	FY21	Y/Y Change
Operating Cash Flow	$23.0M	↓ 67.98%
Investing Cash Flow	$-283.8M	↑ 1284.2%
Financing Cash Flow	$273.4M	↓ 1024.52%

	FY22	Y/Y Change
Operating Cash Flow	$-13.5M	↓ 158.88%
Investing Cash Flow	$-116.4M	↓ 58.97%
Financing Cash Flow	$62.1M	↓ 77.29%

	FY23	Y/Y Change
Operating Cash Flow	$15.3M	↓ 213.35%
Investing Cash Flow	$15.8M	↓ 113.58%
Financing Cash Flow	$-26.7M	↓ 142.94%

	FY24	Y/Y Change
Operating Cash Flow	$38.8M	↑ 152.83%
Investing Cash Flow	$23.0M	↑ 45.27%
Financing Cash Flow	$-54.6M	↑ 104.78%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-6.0M	↓ 157.89%
Investing Cash Flow	$-1000.0K	↑ 69.2%
Financing Cash Flow	$-4.2M	↑ 30200.0%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$15.2M	↓ 352.49%
Investing Cash Flow	$-77.0K	↓ 92.3%
Financing Cash Flow	$-7.8M	↑ 84.94%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$10.3M	↓ 31.96%
Investing Cash Flow	$-64.0K	↓ 16.88%
Financing Cash Flow	$362.0K	↓ 104.61%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$19.3M	↑ 87.3%
Investing Cash Flow	$24.1M	↓ 37762.5%
Financing Cash Flow	$-42.9M	↓ 11938.4%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-19.3M	↓ 200.05%
Investing Cash Flow	$-826.0K	↓ 103.43%
Financing Cash Flow	$947.0K	↓ 102.21%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$25.9M	↓ 234.18%
Investing Cash Flow	$-1.4M	↑ 65.74%
Financing Cash Flow	$-14.7M	↓ 1648.36%

Bioventus Technicals Summary

Sell

Neutral

Buy

Bioventus is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Bioventus Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Bioventus Inc	19.66%	-27.14%	-25.98%	-0.07%	-61.5%
Medtronic Plc	3.87%	-1.59%	4.32%	4.82%	-13.69%
Edwards Lifesciences Corp.	2.55%	13.95%	18.33%	-9.73%	-5.31%
Boston Scientific Corp.	0.09%	0.6%	30.02%	157.38%	154.4%
Stryker Corporation	3.63%	-0.85%	8.87%	89.43%	97.71%
Abbott Laboratories	4.24%	-5.37%	15.72%	26.56%	24.53%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Bioventus Inc	241.67	241.67	2.14	0.64	0.01	0.04	NA	2.41
Medtronic Plc	25.4	25.4	2.14	5.46	0.1	0.05	0.03	37.36
Edwards Lifesciences Corp.	34.03	34.03	4.85	2.5	0.16	0.08	NA	17.94
Boston Scientific Corp.	62.95	62.95	1.84	2.98	0.12	0.05	NA	15.14
Stryker Corporation	51.54	51.54	2.24	13.49	0.14	0.08	0.01	55.43
Abbott Laboratories	16.64	16.64	4.17	5.14	0.31	0.07	0.02	29.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Bioventus Inc	Buy	$485.0M	-61.5%	241.67	0.33%
Medtronic Plc	Buy	$118.0B	-13.69%	25.4	13.63%
Edwards Lifesciences Corp.	Buy	$47.8B	-5.31%	34.03	72.96%
Boston Scientific Corp.	Buy	$156.7B	154.4%	62.95	13.55%
Stryker Corporation	Buy	$149.0B	97.71%	51.54	12.25%
Abbott Laboratories	Buy	$230.9B	24.53%	16.64	32.43%

About Bioventus Inc

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise of various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides nexus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system; and Talisman pulse generator and receiver for peripheral nerve stimulation. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Organization	Bioventus
Employees	950
CEO	Mr. Robert E. Claypoole
Industry	Healthcare

Key Management of Bioventus Inc

Name	Title
Mr. Robert E. Claypoole	President, CEO & Director
Mr. Mark L. Singleton	Senior VP & CFO
Mr. Anthony D'Adamio J.D.	Senior VP, General Counsel & Corporate Secretary
Mr. Mike Crowe B.S., M.B.A.	Senior Vice President of Operations
Mr. David Crawford	Vice President of Investor Relations & Treasurer
Ms. Katrina J. Church J.D.	Senior VP & Chief Compliance Officer
Ms. Helen Leupold	Senior VP & Chief Human Resources Officer
Mr. Dave Venner	Senior VP & GM of Surgical

Important FAQs about investing in BVS Stock from India :

What is Bioventus share price today?

Bioventus share price today is $7.40 as on August 30, 2025 at 1:29 am IST at the close of the market. Bioventus share today touched a day high of $7.45 and a low of $7.30.

What is the 52 week high and 52 week low for Bioventus share?

Bioventus share touched a 52 week high of $14.38 and a 52 week low of $5.81. Bioventus stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $7.40, lower by 48.54% versus the 52 week high.

How to invest in Bioventus Stock (BVS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Bioventus on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Bioventus Shares that will get you 0.2027 shares as per Bioventus share price of $7.40 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Bioventus Stock (BVS) from India?

Indian investors can start investing in Bioventus (BVS) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Bioventus stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Bioventus share’s latest price of $7.40 as on August 30, 2025 at 1:29 am IST, you will get 1.3514 shares of Bioventus. Learn more about fractional shares .

What are the returns that Bioventus has given to Indian investors in the last 5 years?

Bioventus stock has given -61.5% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?